Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20845822 | 1.00 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL20845817 | 1.00 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL20845831 | 0.95 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL20845836 | 0.95 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL20845835 | 0.95 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL21844348 | 0.89 | AKR1A1 (0.88) | AKR1A1AKR1B1 | |
| SCHEMBL21844222 | 0.89 | AKR1A1 (0.88) | AKR1A1AKR1B1 | |
| SCHEMBL21095583 | 0.87 | AKR1A1 (0.86) | AKR1A1AKR1B1 | |
| SCHEMBL23998484 | 0.86 | AKR1A1 (0.80) | AKR1A1AKR1B1 | |
| SCHEMBL23998450 | 0.86 | AKR1A1 (0.90) | AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219905-A1 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF | UNIV CASE WESTERN RESERVE (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219905-A1 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF | UNIV CASE WESTERN RESERVE (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2023-02-23 | — | — | US | disclosed |
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| US-11518748-B2 | Aldoketo reductase inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-12-06 | — | — | US | disclosed |
| US-20210347744-A1 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200268717-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | CASE WESTERN RESERVE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| WO-2020061566-A1 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2019060720-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1A1 8/4885AKR1B1 9/4885 |
| US-20230054339-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | AKR1A1 3/4885AKR1B1 1/4885 |
| US-11518748-B2 | Aldoketo reductase inhibitors and uses thereof | AKR1B1, AKR1A1, AKR1C2 | AKR1A1 2/4885AKR1B1 1/4885 |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1A1 8/4885AKR1B1 9/4885 |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | AKR1A1 3/4885AKR1B1 1/4885 |
| US-20200268717-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1A1 8/4885AKR1B1 9/4885 |
| US-20210347744-A1 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF | AKR1B1, AKR1A1, AKR1C2 | AKR1A1 2/4885AKR1B1 1/4885 |
| US-20230219905-A1 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF | AKR1B1, AKR1A1, AKR1C2 | AKR1A1 2/4885AKR1B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.